UTHR · UNITED THERAPEUTICS Corp
$499.73
-1.54 (-0.31%)
At close · Aug 14
Market Cap
$21.95B
Shares
42.89M
UNITED THERAPEUTICS Corp Earnings Call Transcripts
Every quarterly earnings call for UNITED THERAPEUTICS Corp (UTHR) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲16%
$516.00M
$239.30M
'22 Q3
22-11-02
▲18.4%
$491.50M
$132.10M
'22 Q4
23-02-22
▲9.7%
$506.90M
$240.90M
'23 Q1
23-05-03
▲27.8%
$596.50M
$259.20M
'23 Q2
23-08-02
▲18.1%
$609.40M
$267.60M
'23 Q3
23-11-01
▲25.1%
$614.70M
$217.10M
'23 Q4
24-02-21
▲33.7%
$677.70M
$306.60M
'24 Q1
24-05-01
▲19.8%
$714.90M
$278.10M
'24 Q2
24-07-31
▲22.9%
$748.90M
$309.10M
'24 Q3
24-10-30
▲19.7%
$735.90M
$301.30M
'24 Q4
25-02-26
▲17.2%
$794.40M
$322.20M
'25 Q1
25-04-30
▲11.7%
$798.60M
$309.50M
'25 Q2
25-09-28
▲6.8%
$799.50M
$338.70M
'25 Q3
25-10-29
▲7.4%
$790.20M
$364.30M
'25 Q4
26-02-25
▼1.6%
$781.50M
$274.90M
'26 Q1
26-05-06
LATEST
▼1.9%
$783.30M
$333.00M
'26 Q2
26-08-05
Earnings call
FY26 · Q2
2026-08-05
UNITED THERAPEUTICS Corp Q2 FY2026 Earnings Call
Positive tone
Tyvaso nebulized IPF (Teton) franchise and label expansion
Quarterly revenue performance and commercial momentum
Sales force expansion ahead of new launches
Revenue
$783.30M
▼ 1.9% YoY Diluted EPS
$7.27
▲ 13.4% YoY Gross margin
87.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
UNITED THERAPEUTICS Corp Q1 FY2026 Earnings Call
Confident tone
Tyvaso/TETON for IPF
Ralinepag Phase III outcomes in PAH
New RALDPI inhaled product launch
Revenue
$781.50M
▼ 1.6% YoY Diluted EPS
$5.82
▼ 12.2% YoY Gross margin
82.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-09
Leerink Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-25
UNITED THERAPEUTICS Corp Q4 FY2025 Earnings Call
Confident tone
Tyvaso for IPF (TETON program)
Tresmi soft mist inhaler
Ralinepag once-daily super prostacyclin
Revenue
$790.20M*
▲ 7.4% YoY Gross margin
86.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-01-12
44th Annual J.P. Morgan Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2025-11-18
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2025-11-10
UBS Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-10-29
UNITED THERAPEUTICS Corp Q3 FY2025 Earnings Call
Confident tone
TETON clinical program in pulmonary fibrosis
Tyvaso DPI franchise and competitive positioning
Business development and partnering interest
Revenue
$799.50M
▲ 6.8% YoY Diluted EPS
$7.16
▲ 12.1% YoY Gross margin
87.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-09-28
UNITED THERAPEUTICS Corp Q2 FY2025 Earnings Call
Confident tone
TETON IPF and PPF clinical program
Foundational commercial growth / Tyvaso franchise
Competitive threat from Liquidia / YUTREPIA (TPIP)
Revenue
$798.60M
▲ 11.7% YoY Diluted EPS
$6.41
▲ 9.6% YoY Gross margin
89.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2025-09-08
Morgan Stanley 23rd Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q1
2025-04-30
UNITED THERAPEUTICS Corp Q1 FY2025 Earnings Call
Confident tone
Treprostinil Product Franchise
Registration Studies and Regulatory Milestones
Record Quarterly Revenue Growth
Revenue
$794.40M
▲ 17.2% YoY Diluted EPS
$6.63
▲ 7.5% YoY Gross margin
88.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2025-03-11
Leerink Partners Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2025-03-03
TD Cowen Health Care Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY24 · Q4
2025-02-26
UNITED THERAPEUTICS Corp Q4 FY2024 Earnings Call
Revenue
$735.90M*
▲ 19.7% YoY Gross margin
89.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2025-01-13
J.P. Morgan Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY24 · Q3
2024-10-30
UNITED THERAPEUTICS Corp Q3 FY2024 Earnings Call
Confident tone
Record commercial revenue and product growth
Revolution wave – xenotransplantation and organ alternatives
Capital allocation – share repurchases and M&A
Revenue
$748.90M
▲ 22.9% YoY Diluted EPS
$6.39
▲ 18.8% YoY Gross margin
88.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-31
UNITED THERAPEUTICS Corp Q2 FY2024 Earnings Call
Confident tone
Foundational product confidence
Ralinepag PAH pipeline risk
Tyvaso franchise leadership
Revenue
$714.90M
▲ 19.8% YoY Diluted EPS
$5.85
▲ 11.6% YoY Gross margin
89.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-01
UNITED THERAPEUTICS Corp Q1 FY2024 Earnings Call
Confident tone
Ralinepag (OUTCOMES trial) in PAH
Xenotransplantation / organ manufacturing
Sotatercept competitive landscape
Revenue
$677.70M
▲ 33.7% YoY Diluted EPS
$6.17
▲ 27% YoY Gross margin
89.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-21
UNITED THERAPEUTICS Corp Q4 FY2023 Earnings Call
Confident tone
Tyvaso franchise and PH-ILD growth
TETON pulmonary fibrosis program
Manufactured organs and xenotransplantation
Revenue
$614.70M*
▲ 25.1% YoY Gross margin
88.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-01
UNITED THERAPEUTICS Corp Q3 FY2023 Earnings Call
Revenue
$609.40M
▲ 18.1% YoY Diluted EPS
$5.38
▲ 9.6% YoY Gross margin
88.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
UNITED THERAPEUTICS Corp Q2 FY2023 Earnings Call
Revenue
$596.50M
▲ 27.8% YoY Diluted EPS
$5.24
▲ 117.4% YoY Gross margin
89.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
UNITED THERAPEUTICS Corp Q1 FY2023 Earnings Call
Revenue
$506.90M
▲ 9.7% YoY Diluted EPS
$4.86
▼ 3.4% YoY Gross margin
89.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-22
UNITED THERAPEUTICS Corp Q4 FY2022 Earnings Call
Revenue
$491.50M*
▲ 18.4% YoY Gross margin
88.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
UNITED THERAPEUTICS Corp Q3 FY2022 Earnings Call
Revenue
$516.00M
▲ 16% YoY Diluted EPS
$4.91
▲ 43.6% YoY Gross margin
92.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
UNITED THERAPEUTICS Corp Q2 FY2022 Earnings Call
Revenue
$466.90M
▲ 4.6% YoY Diluted EPS
$2.41
▼ 34% YoY Gross margin
93.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
UNITED THERAPEUTICS Corp Q1 FY2022 Earnings Call
Revenue
$461.90M
▲ 21.8% YoY Diluted EPS
$5.03
▲ 724.6% YoY Gross margin
94.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
UNITED THERAPEUTICS Corp Q4 FY2021 Earnings Call
Revenue
$415.20M*
▲ 7.9% YoY Gross margin
91.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
UNITED THERAPEUTICS Corp Q3 FY2021 Earnings Call
Revenue
$444.70M
▲ 17% YoY Diluted EPS
$3.42
▼ 10.9% YoY Gross margin
93.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
UNITED THERAPEUTICS Corp Q2 FY2021 Earnings Call
Revenue
$446.50M
▲ 23.3% YoY Diluted EPS
$3.65
▲ 51.5% YoY Gross margin
91.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
UNITED THERAPEUTICS Corp Q1 FY2021 Earnings Call
Revenue
$379.10M
▲ 6.4% YoY Diluted EPS
$0.61
▼ 80.4% YoY Gross margin
93.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-24
UNITED THERAPEUTICS Corp Q4 FY2020 Earnings Call
Revenue
$384.90M*
▲ 23.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-28
UNITED THERAPEUTICS Corp Q3 FY2020 Earnings Call
Revenue
$380.10M
▼ 5.3% YoY Diluted EPS
$3.84
▲ 27.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-29
UNITED THERAPEUTICS Corp Q2 FY2020 Earnings Call
Revenue
$362.00M
▼ 3.1% YoY Diluted EPS
$2.41
▼ 48.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-29
UNITED THERAPEUTICS Corp Q1 FY2020 Earnings Call
Revenue
$356.30M
▼ 1.7% YoY Diluted EPS
$3.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-26
UNITED THERAPEUTICS Corp Q4 FY2019 Earnings Call
Revenue
$311.10M
▼ 18.4% YoY Diluted EPS
$1.20
▼ 18.9% YoY Gross margin
90.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–36 of 36 earnings calls
Key facts
CIK
1082554
CUSIP
91307C102
13F (30d)
806 filings
786 filers
Visit website
Investor relations